Literature DB >> 26080431

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Joseph Ciccolini1, Sébastien Benzekry2, Bruno Lacarelle3, Dominique Barbolosi4, Fabrice Barlési5.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26080431      PMCID： PMC4500227          DOI： 10.1073/pnas.1506689112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  3 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Authors:  Rebecca S Heist; Dan G Duda; Dushyant V Sahani; Marek Ancukiewicz; Panos Fidias; Lecia V Sequist; Jennifer S Temel; Alice T Shaw; Nathan A Pennell; Joel W Neal; Leena Gandhi; Thomas J Lynch; Jeffrey A Engelman; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

3.  Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Authors:  Marlous Arjaans; Thijs H Oude Munnink; Sjoukje F Oosting; Anton G T Terwisscha van Scheltinga; Jourik A Gietema; Erik T Garbacik; Hetty Timmer-Bosscha; Marjolijn N Lub-de Hooge; Carolina P Schröder; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701
  3 in total
  5 in total

1.  Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.

Authors:  Dan G Duda; Rebecca S Heist; Dushyant V Sahani; Triantafyllos Stylianopoulos; Jeffrey A Engelman; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-16       Impact factor: 11.205

2.  Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.

Authors:  Dominique Barbolosi; Ilyssa Summer; Christophe Meille; Raphaël Serre; Antony Kelly; Slimane Zerdoud; Claire Bournaud; Claire Schvartz; Michel Toubeau; Marie-Elisabeth Toubert; Isabelle Keller; David Taïeb
Journal:  Oncotarget       Date:  2017-06-13

3.  Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.

Authors:  Wei-Chun Chen; Jiantai Timothy Qiu; Chyong-Huey Lai; Huei-Jean Huang; Cheng-Tao Lin; Min-Yu Chen; Hung-Hsueh Chou; Kuan-Gen Huang; Ting-Chang Chang
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

4.  Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.

Authors:  Benjamin K Schneider; Arnaud Boyer; Joseph Ciccolini; Fabrice Barlesi; Kenneth Wang; Sebastien Benzekry; Jonathan P Mochel
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-05-09

5.  Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Authors:  Diane-Charlotte Imbs; Raouf El Cheikh; Arnaud Boyer; Joseph Ciccolini; Céline Mascaux; Bruno Lacarelle; Fabrice Barlesi; Dominique Barbolosi; Sébastien Benzekry
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.